key: cord-0980055-afewbb3c
authors: Hoffmann, Markus; Krüger, Nadine; Schulz, Sebastian; Cossmann, Anne; Rocha, Cheila; Kempf, Amy; Nehlmeier, Inga; Graichen, Luise; Moldenhauer, Anna-Sophie; Winkler, Martin S.; Lier, Martin; Dopfer-Jablonka, Alexandra; Jäck, Hans-Martin; Behrens, Georg M.N.; Pöhlmann, Stefan
title: The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic
date: 2021-12-24
journal: Cell
DOI: 10.1016/j.cell.2021.12.032
sha: 546727a50fea87bd3eaeabc19c33c2ea3ad4312e
doc_id: 980055
cord_uid: afewbb3c

The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become globally dominant. Further, the high number of mutations in the viral spike-protein raised concerns that the virus might evade antibodies induced by infection or vaccination. Here, we report that the Omicron spike was resistant against most therapeutic antibodies but remained susceptible to inhibition by Sotrovimab. Similarly, the Omicron spike evaded neutralization by antibodies from convalescent or BNT162b2-vaccinated individuals with 10- to 44-fold higher efficiency than the spike of the Delta variant. Neutralization of the Omicron spike by antibodies induced upon heterologous ChAdOx1/BNT162b2-vaccination or vaccination with three doses of BNT162b2 was more efficient, but the Omicron spike still evaded neutralization more efficiently than the Delta spike. These findings indicate that most therapeutic antibodies will be ineffective against the Omicron variant and that double immunization with BNT162b2 might not adequately protect against severe disease induced by this variant.

CoV-2 and related viruses and was found to protect patients from 174 2021). Since the Omicron spike harbors several mutations within the structures that are 175 recognized by these antibodies ( Figure 2B ), we investigated whether the antibodies were still able 176 to neutralize the Omicron spike. All antibodies inhibited entry driven by the B.1 spike in a robust 177 and concentration dependent manner while a control immunoglobulin was inactive ( Figure 2C ). 178 In contrast, entry driven by the Omicron spike was fully resistant against Bamlanivimab, 179 Etesevimab and Imdevimab and largely resistant against Casirivimab. In agreement with these 180 findings, a cocktail of Bamlanivimab and Etesevimab failed to inhibit entry mediated by Omicron 181 spike while inhibition by a cocktail of Casirivimab and Imdevimab was inefficient ( Figure 2C ).

In contrast, Sotrovimab was active against Omicron spike, although inhibition was slightly less 183 efficient than that measured for B.1 spike ( Figure 2C ). In sum, the Omicron spike is resistant The mRNA-based vaccine BNT efficiently protects against 198 2020) and is frequently used in Europe and the USA. Sera collected within one to three months 199 after the second dose of BNT (10 sera were collected within one month, one serum was collected heterologous AZ/BNT vaccination (supplemental table S2) exhibited higher neutralizing activity as compared to sera collected within 3 months after BNT/BNT vaccination ( Figure 3C ).

Inhibition of Omicron spike-driven entry by sera from AZ/BNT vaccinated individuals was 14-217 fold less efficient as compared to B.1. spike but only 3-fold less efficient relative to Delta spike 218 ( Figure 3C ). Further, inhibition of Omicron spike by sera collected within 1 months of AZ/BNT 219 vaccination was comparable to inhibition of Delta spike by sera obtained within 3 months after 220 BNT/BNT vaccination ( Figure 3B and C), a time interval during which the vaccine provides 221 more than 90% protection from severe COVID-19. 

The findings that the Omicron spike facilitated efficient entry into several human cell 253 lines and robustly bound human ACE2 suggest that the Omicron variant readily infects human 254 cells. Nevertheless, some peculiarities of host cell entry driven by the Omicron spike relative to 255 the B.1 spike were noted. The Omicron spike mediated slightly but significantly augmented entry 256 into cell lines which only allow for cathepsin L-(293T, Huh-7, A549-ACE2) but not TMPRSS2-257 dependent entry, due to low or absent TMPRSS2 expression (Hoffmann et al., 2020b) . We 258 previously observed a similar phenotype for the S protein of another African SARS-CoV-2 259 lineage, A.30 (Arora et al., 2021a) , and the mutations in spike responsible for this phenotype 260 remain to be determined. Further, the Omicron spike used ACE2 proteins from different animal 261 species with high efficiency for entry. The efficient usage of murine ACE2 is in keeping with the 262 presence of mutations K417N and N501Y, which can also emerge upon SARS-CoV-2 adaptation to experimentally infected mice (Huang et al., 2021; Sun et al., 2021; Zhang et al., 2021b) . In 264 addition, the Omicron spike harbors mutations Q493R and Q498R that are related to exchanges 265 Q493K and Q498H, which were also detected in mouse-adapted SARS-CoV-2 (Huang et al., 266 2021; Sun et al., 2021; Zhang et al., 2021b) . However, some of these mutations are present in 267 other VOC and cannot be taken as evidence that the Omicron variant may have evolved in 268 infected mice in the wild. In addition, the Omicron spike was able to use ACE2 from the 

Neutralizing antibody responses are also believed to be critical for protection against Figure S1 : Cell entry driven by the spike proteins of VOC (related to Figure 1F ).

Pseudotype entry data presented in Figure 1F normalized against the assay background. The Table Titles   666  Table S1 : COVID-19 patient data (related to Figure 3 

SARS-CoV-2 variants B.1.351 and P.1 774 escape from neutralizing antibodies

A Multibasic Cleavage Site in the 776

Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 mutations 784 acquired in mink reduce antibody-mediated neutralization

SARS-CoV-2 D614G variant exhibits efficient 788 replication ex vivo and transmission in vivo

Q493K and Q498H substitutions in Spike promote adaptation of SARS-791

CoV-2 in mice

The neutralizing 794 antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised 878 controlled trials in Brazil, South Africa, and the UK